Study of Vitamin D3 Substitution to Patients With Primary Immunodeficiency

• Status: Completed
• Trial end date: 2011-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Hypothesis: Cholecalciferol (vitamin D3) prevent respiratory tract infections in patients with primary immunodeficiency.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Karolinska University Hospital
• Treatments: Cholecalciferol; Ergocalciferols; Vitamin D; Vitamins

Criteria

Inclusion Criteria:

• Age 18-75

• Increased number of respiratory tract infections

• At least 42 days of infections during 2008 or 2009

• S-25 OH vitamin D3 < 250 nM

• Not planning a pregnancy during the coming year

• Accepting the use of contraceptives during 1 year

Exclusion Criteria:

• Continuous antibiotic treatment

• Hypercalcemia

• Sarcoidosis

• Kidney disease

• Tuberculosis

• Pregnancy

• Kidney stone

• Heart medication (glycosides)